PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29943354-9	2018	In addition, VPA treatment led to the overexpression of Oct4 and Nanog.	Valproic Acid	13-16	POU class 5 homeobox 1	Homo sapiens	56-60	
30509303-10	2018	RESULTS: We found that DAC and VPA induce an increased expression of stem markers including CD133, OCT4, SOX2 and NANOG, and an increased ability in sarcospheres and colonies formation efficiency.	Valproic Acid	31-34	POU class 5 homeobox 1	Homo sapiens	99-103	
24361750-0	2014	Valproic acid enhances Oct4 promoter activity through PI3K/Akt/mTOR pathway activated nuclear receptors.	Valproic Acid	0-13	POU class 5 homeobox 1	Homo sapiens	23-27	
28153093-4	2017	Mechanistic insights into the process of VPA-induced reprogramming revealed that it was dependent on OCT4 promoter activation, which was achieved independently of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway or GSK3beta inhibition but was concomitant with the presence of acetylated histones H3K9 and H3K56, which promote pluripotency.	Valproic Acid	41-44	POU class 5 homeobox 1	Homo sapiens	101-105	
25826722-4	2015	Herein, we demonstrate that acute combinatorial treatment with the proteasome inhibitors MG101 or MG132 and the histone deacetylase (HDAC) inhibitor valproic acid (VPA) increases gene expression of the pluripotency marker Oct3/4, and that MG101 alone is as effective as VPA in the induction of Oct3/4 mRNA expression in fibroblasts.	Valproic Acid	149-162	POU class 5 homeobox 1	Homo sapiens	222-228	
25826722-4	2015	Herein, we demonstrate that acute combinatorial treatment with the proteasome inhibitors MG101 or MG132 and the histone deacetylase (HDAC) inhibitor valproic acid (VPA) increases gene expression of the pluripotency marker Oct3/4, and that MG101 alone is as effective as VPA in the induction of Oct3/4 mRNA expression in fibroblasts.	Valproic Acid	149-162	POU class 5 homeobox 1	Homo sapiens	294-300	
25826722-4	2015	Herein, we demonstrate that acute combinatorial treatment with the proteasome inhibitors MG101 or MG132 and the histone deacetylase (HDAC) inhibitor valproic acid (VPA) increases gene expression of the pluripotency marker Oct3/4, and that MG101 alone is as effective as VPA in the induction of Oct3/4 mRNA expression in fibroblasts.	Valproic Acid	164-167	POU class 5 homeobox 1	Homo sapiens	222-228	
25826722-4	2015	Herein, we demonstrate that acute combinatorial treatment with the proteasome inhibitors MG101 or MG132 and the histone deacetylase (HDAC) inhibitor valproic acid (VPA) increases gene expression of the pluripotency marker Oct3/4, and that MG101 alone is as effective as VPA in the induction of Oct3/4 mRNA expression in fibroblasts.	Valproic Acid	164-167	POU class 5 homeobox 1	Homo sapiens	294-300	
25232932-6	2015	We found that saRNA-induced OCT4 activation can be further enhanced by a histone deacetylase inhibitor, valproic acid.	Valproic Acid	104-117	POU class 5 homeobox 1	Homo sapiens	28-32	
22387464-8	2012	We therefore targeted the activity of epigenetic modulators and found that chemical inhibition of histone deacetylases by valproic acid or DNA methyltransferases by 5-aza-2"-deoxycytidine facilitated dTALE-mediated activation of the epigenetically silenced oct4 promoter in NSCs.	Valproic Acid	122-135	POU class 5 homeobox 1	Homo sapiens	257-261	
23050522-6	2013	Supplementation with VPA for 5 days further upregulated OCT4, KLF4, and SOX2, and induced expression of NANOG, SSEA3, TRA-1-60, and TRA-1-81, with cells now able to form EBs and teratomas.	Valproic Acid	21-24	POU class 5 homeobox 1	Homo sapiens	56-60	
22860916-5	2012	Treatment with valproic acid, an HDAC inhibitor, could significantly increase the expression of Oct4 in C-33A cells, but only slightly increased Oct4 in CaSki cells.	Valproic Acid	15-28	POU class 5 homeobox 1	Homo sapiens	96-100	
22860916-5	2012	Treatment with valproic acid, an HDAC inhibitor, could significantly increase the expression of Oct4 in C-33A cells, but only slightly increased Oct4 in CaSki cells.	Valproic Acid	15-28	POU class 5 homeobox 1	Homo sapiens	145-149	
18568017-3	2008	In particular, valproic acid (VPA), an HDAC inhibitor, improves reprogramming efficiency by more than 100-fold, using Oct4-GFP as a reporter.	Valproic Acid	15-28	POU class 5 homeobox 1	Homo sapiens	118-122	
18568017-3	2008	In particular, valproic acid (VPA), an HDAC inhibitor, improves reprogramming efficiency by more than 100-fold, using Oct4-GFP as a reporter.	Valproic Acid	30-33	POU class 5 homeobox 1	Homo sapiens	118-122	
33805347-8	2021	In summary, 5AZ, VPA, CHIR99021, and A83-01 induced the expression of OCT4 and SOX2, two critical genes for iPSC.	Valproic Acid	17-20	POU class 5 homeobox 1	Homo sapiens	70-74	
20564199-0	2010	Valproic acid enhances Oct4 promoter activity in myogenic cells.	Valproic Acid	0-13	POU class 5 homeobox 1	Homo sapiens	23-27	
18849973-3	2008	Here we report that valproic acid (VPA), a histone deacetylase inhibitor, enables reprogramming of primary human fibroblasts with only two factors, Oct4 and Sox2, without the need for the oncogenes c-Myc or Klf4.	Valproic Acid	20-33	POU class 5 homeobox 1	Homo sapiens	148-152	
18849973-3	2008	Here we report that valproic acid (VPA), a histone deacetylase inhibitor, enables reprogramming of primary human fibroblasts with only two factors, Oct4 and Sox2, without the need for the oncogenes c-Myc or Klf4.	Valproic Acid	35-38	POU class 5 homeobox 1	Homo sapiens	148-152